Strategic collaborations Remepy partners with pharma companies to bring Hybrid Drugs to market, presenting a clear pathway for co-development and licensing opportunities that align with pharmaceutical pipeline needs.

AI driven value Digital Molecules are AI-enabled software interventions designed to optimize drug performance, offering a compelling upsell for pharma partners seeking digital therapeutics or personalized treatment protocols.

Recent funding A substantial Series A totaling 36 million USD indicates investor confidence and capital availability for scaling partnerships, clinical programs, and go-to-market initiatives.

Growth potential Company size and revenue positioning (51-200 employees, $10-25M revenue) signals room for expansion, channel partnerships, and enterprise-level collaborations with mid- to large-sized pharma players.

Security and compliance Adherence to NIST Cybersecurity Framework and CompTIA Security+ aligns with rigorous pharma data standards, easing due diligence for potential clients requiring strong cybersecurity posture.